CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01%
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CureVac NV
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Other Liabilities
€48.1m
CAGR 3-Years
-54%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Other Liabilities
€459.2m
CAGR 3-Years
62%
CAGR 5-Years
13%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Other Liabilities
€1.3B
CAGR 3-Years
35%
CAGR 5-Years
417%
CAGR 10-Years
37%
Immatics NV
NASDAQ:IMTX
Other Liabilities
€115.5m
CAGR 3-Years
11%
CAGR 5-Years
95%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Other Liabilities
€109m
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
5%
Formycon AG
XETRA:FYB
Other Liabilities
€187.6m
CAGR 3-Years
N/A
CAGR 5-Years
273%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Other Liabilities?
Other Liabilities
48.1m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Other Liabilities amounts to 48.1m EUR.

What is CureVac NV's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
-6%

Over the last year, the Other Liabilities growth was -64%. The average annual Other Liabilities growth rates for CureVac NV have been -54% over the past three years , -6% over the past five years .

Back to Top